Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma

NCT01417143 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01417143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01417143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
November 30, 2014
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma